keyword
MENU ▼
Read by QxMD icon Read
search

colorectal cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/28822989/cellular-prion-protein-enhances-drug-resistance-of-colorectal-cancer-cells-via-regulation-of-a-survival-signal-pathway
#1
Jun Hee Lee, Chul Won Yun, Sang Hun Lee
Anti-cancer drug resistance is a major problem in colorectal cancer (CRC) research. Although several studies have revealed the mechanism of cancer drug resistance, molecular targets for chemotherapeutic combinations remain elusive. To address this issue, we focused on the expression of cellular prion protein (PrP(C)) in 5-FU-resistant CRC cells. In 5-FU-resistant CRC cells, PrP(C) expression is significantly increased, compared with that in normal CRC cells. In the presence of 5-FU, PrP(C) increased CRC cell survival and proliferation by maintaining the activation of the PI3K-Akt signaling pathway and the expression of cell cycle-associated proteins, including cyclin E, CDK2, cyclin D1, and CDK4...
August 21, 2017: Biomolecules & Therapeutics
https://www.readbyqxmd.com/read/28821938/depth-of-response-predicts-the-clinical-outcome-of-advanced-her2-positive-gastric-cancer-to-trastuzumab-based-first-line-chemotherapy
#2
Shigenori Kadowaki, Toshiki Masuishi, Tetsuya Eto, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Masahiro Tajika, Yasumasa Niwa, Yasushi Yatabe, Kei Muro
PURPOSE: Accumulating evidence suggests that response-related parameters such as depth of response (DpR) might be associated with survival in colorectal cancer, which has not been shown in gastric cancer. This study aimed to evaluate whether DpR was associated with clinical outcomes in HER2-positive AGC patients treated with trastuzumab-based chemotherapy. METHODS: Fifty-seven HER2-positive AGC patients who were treated with trastuzumab in combination with fluoropyrimidines plus cisplatin therapy as first-line treatment were retrospectively enrolled...
August 18, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28820635/effects-of-autologous-cytokine-induced-killer-cells-infusion-in-colorectal-cancer-patients-a-prospective-study
#3
Hao Peng, Meng Yao, Hongwei Fan, Liwei Song, Jinwen Sun, Zheng Zhou, Yunfeng Du, Keyu Lu, Tao Li, Aiguo Yin, Jianhua Xu, Shidong Wei
AIM: To evaluate the efficacy and safety of postoperative adjuvant immunotherapy with cytokine-induced killer (CIK) cells in combination with chemotherapy (CT) in colorectal cancer (CRC) patients. MATERIALS AND METHODS: A total of 46 patients were randomly assigned to either group 1 (control group) or group 2 (CIK group) using blocked randomization. Both groups received the FOLFOX4 (5-fluorouridine, leucovorin, and oxaliplatin) CT. In the CIK group, patients were given CIK cell infusion after FOLFOX4 CT...
August 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28819759/melatonin-increases-the-effect-of-5-fluorouracil-based-chemotherapy-in-human-colorectal-adenocarcinoma-cells-in-vitro
#4
Roberto Pariente, Ignacio Bejarano, Ana Beatriz Rodríguez, José Antonio Pariente, Javier Espino
Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects. Moreover, it has been proven that melatonin in combination with chemotherapeutic agents enhances chemotherapy-triggered apoptosis in several types of cancer. Therefore, this study was intended to evaluate whether melatonin is able to strengthen the anti-cancer potential of different chemotherapeutic drugs in human colorectal adenocarcinoma HT-29 cells. We found that treatment with 20 µM cisplatin (CIS) or 1 mM 5-fluorouracil (5-FU) for 72 h induced a decrease in HT-29 cell viability...
August 17, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28818109/metastatic-colorectal-cancer-responsive-to-regorafenib-for-2-years-a-case-report
#5
Kenji Yoshino, Dai Manaka, Ryo Kudo, Shunpei Kanai, Eisei Mitsuoka, Satoshi Kanto, Shinya Hamasu, Sayuri Konishi, Ryuta Nishitai
BACKGROUND: Regorafenib is an oral multikinase inhibitor that has been demonstrated as clinically effective in patients with metastatic colorectal cancer in phase III studies. Although disease control was achieved in 40% of the pretreated patients with metastatic colorectal cancer in the pivotal studies, radiological response has rarely been reported. Severe adverse events associated with regorafenib are known to occur during the first and second courses of treatment. We present a case of a 62-year-old Japanese patient whose metastatic colorectal cancer has been responding to treatment with regorafenib for 2 years...
August 18, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28817175/drug-development-for-breast-colorectal-and-non-small-cell-lung-cancers-from-1979-to-2014
#6
Nancy A Nixon, Omar F Khan, Hasiba Imam, Patricia A Tang, Jose Monzon, Haocheng Li, Gavin Sun, Doreen Ezeife, Sunil Parimi, Scot Dowden, Vincent C Tam
BACKGROUND: Understanding the drug development pathway is critical for streamlining the development of effective cancer treatments. The objective of the current study was to delineate the drug development timeline and attrition rate of different drug classes for common cancer disease sites. METHODS: Drugs entering clinical trials for breast, colorectal, and non-small cell lung cancer were identified using a pharmaceutical business intelligence database. Data regarding drug characteristics, clinical trials, and approval dates were obtained from the database, clinical trial registries, PubMed, and regulatory Web sites...
August 17, 2017: Cancer
https://www.readbyqxmd.com/read/28814275/randomized-study-comparing-full-dose-monotherapy-s-1-followed-by-irinotecan-and-reduced-dose-combination-therapy-s-1-oxaliplatin-followed-by-s-1-irinotecan-as-initial-therapy-for-older-patients-with-metastatic-colorectal-cancer-nordic-9
#7
Stine Braendegaard Winther, Pia Österlund, Åke Berglund, Bengt Glimelius, Camilla Qvortrup, Halfdan Sorbye, Per Pfeiffer
BACKGROUND: Metastatic colorectal cancer (mCRC) is a disease of older age, but there is a relative lack of knowledge about effects of chemotherapy in older patients as they are under-represented in clinical trials. Little data can guide whether the strategy in older mCRC patients should be a sequential full-dose monotherapy chemotherapy approach or a dose-reduced combination chemotherapy approach. The oral 5FU prodrug S-1 seems to have less side effects than capecitabine and should be an optimal drug for older patients, but few data are available...
August 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28813196/hepatic-parenchymal-heterogeneity-as-a-marker-for-oxaliplatin-induced-sinusoidal-obstruction-syndrome-correlation-with-treatment-response-of-colorectal-cancer-liver-metastases
#8
Na Yeon Han, Beom Jin Park, Kyung Sook Yang, Min Ju Kim, Deuk Jae Sung, Ki Choon Sim, Sung Bum Cho
OBJECTIVE: The objective of our study was to evaluate the influence of oxaliplatin-based chemotherapy (OBC)-induced hepatic parenchymal heterogeneity detected on contrast-enhanced CT scans on response of liver metastasis. We chose to study hepatic parenchymal heterogeneity on the basis of the assumption that hepatic parenchymal heterogeneity may indicate the presence of chemotherapy-induced sinusoidal obstruction syndrome (SOS). MATERIALS AND METHODS: For this retrospective study, 104 patients with hepatic metastases from colorectal cancer (male-female ratio, 66:38; age range, 20-80 years) who had undergone OBC and serial CT studies were consecutively registered...
August 16, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28812134/elevated-tumor-to-liver-uptake-ratio-tlr-from-18-f-fdg-pet-ct-predicts-poor-prognosis-in-stage-iia-colorectal-cancer-following-curative-resection
#9
Jun Huang, Liang Huang, Jiaming Zhou, Yinghua Duan, Zhanwen Zhang, Xiaoyan Wang, Pinzhu Huang, Shuyun Tan, Ping Hu, Jianping Wang, Meijin Huang
PURPOSE: The prognostic value of the tumor-to-liver uptake ratio (TLR) from 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in the early stage of colorectal cancer (CRC) is unclear. Notably, some stage IIA CRC patients experience early recurrence even after curative resection and might benefit from neoadjuvant or adjuvant chemotherapy. This study aims to evaluate whether elevated TLR from (18)F-FDG-PET/CT can predict poor prognosis in stage IIA CRC patients undergoing curative resection...
August 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28810580/connexin-43-enhances-paclitaxel-cytotoxicity-in-colorectal-cancer-cell-lines
#10
Siqi Wang, Shiwu Zhang, Zhenying Zhao, Chunze Zhang, Xiaoyun Yang, Yijia Wang
Colorectal cancer has a relatively low sensitivity to paclitaxel. The purpose of this study was to investigate the role of connexin 43 (Cx43), which is a structural component of gap junctional communication (GJC), in paclitaxel cytotoxicity in colorectal cancer cells. Three colorectal cancer cell lines (HCT106, HCT116 and LoVo) were transfected with Cx43 and used to examine paclitaxel cytotoxicity. A western blot assay was used to confirm Cx43 expression in transfected cell lines as well as the expression of several proteins that are associated with paclitaxel cytotoxicity...
August 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28809079/changes-in-the-use-of-erythropoiesis-stimulating-agents-esas-and-red-blood-cell-transfusion-in-patients-with-cancer-amidst-regulatory-and-reimbursement-changes
#11
Prasad L Gawade, Jesse A Berlin, David H Henry, Dianne Tomita, Barry D Brooks, Janet Franklin, Brian D Bradbury, Cathy W Critchlow
PURPOSE: Evaluate changes in use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in cancer patients receiving myelosuppressive chemotherapy following regulatory and reimbursement actions. METHODS: Calendar year patient cohorts (2005-2013) with breast, colorectal, lung, multiple myeloma, non-Hodgkin lymphoma, ovarian, or prostate cancer and receiving myelosuppressive chemotherapy were identified within the Marketscan database. Incidence of ESA treatment and transfusion were estimated in each year, as was median number of ESA administrations...
August 14, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28804633/fractalkine-c-x3-c-motif-chemokine-ligand-1-as-a-potential-biomarker-for-depression-and-anxiety-in-colorectal-cancer-patients
#12
Diego Oliveira Miranda, Elen Anatriello, Lucas Ribeiro Azevedo, Jessica Cristina Santos, Jessica Fernanda Correa Cordeiro, Fernanda Maris Peria, Milena Flória-Santos, Gabriela Pereira-Da-Silva
Fractalkine, a unique chemokine of the CX3C subfamily, is involved in the pathogenesis of different types of cancer and also in non-immune mechanisms associated with psychiatric disorders. The aim of the present study was to investigate whether there is a correlation between anxiety, depression and fractalkine serum levels in colorectal cancer (CRC) patients in different stages of antitumor therapy. Four groups of patients undergoing treatment (n=20 per group) were evaluated: Patients with CRC who did not undergo surgical resection of the tumor; patients who underwent resection and who did not start adjuvant therapy; patients undergoing chemotherapy for ~3 months; and patients who had completed adjuvant chemotherapy regimen for ~6 months...
August 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28803938/organoids-as-preclinical-models-to-improve-intraperitoneal-chemotherapy-effectiveness-for-colorectal-cancer-patients-with-peritoneal-metastases-preclinical-models-to-improve-hipec
#13
P Roy, C Canet-Jourdan, M Annereau, O Zajac, M Gelli, S Broutin, L Mercier, A Paci, F Lemare, M Ducreux, D Elias, D Malka, V Boige, D Goéré, F Jaulin
BACKGROUND: Peritoneal metastases (PM), corresponding to tumor implants into the peritoneal cavity, are associated with impaired prognosis and low responsiveness to systemic chemotherapy. A new therapeutic approach has dramatically changed the prognosis of patients with PM from colorectal cancer (CRC), consisting in the association of a complete cytoreductive surgery followed by intraperitoneal chemotherapy associated to hyperthermia (HIPEC). Many drugs have been administered intraperitoneally, but no clear consensus has been approved...
August 10, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28803718/total-neoadjuvant-therapy-a-shifting-paradigm-in-locally-advanced-rectal-cancer-management
#14
REVIEW
Aaron J Franke, Hiral Parekh, Jason S Starr, Sanda A Tan, Atif Iqbal, Thomas J George
Colorectal carcinoma is the second leading cause of cancer-related deaths in the United States, with rectal cancer accounting for approximately one-third of newly diagnosed cases, thus representing a major socioeconomic health burden. Although minimally invasive procedures (ie, transanal excision) may be appropriate for a subset of patients with small, superficially invasive tumors, a more comprehensive trimodality approach with neoadjuvant chemoradiotherapy, total mesorectal excision, and systemic chemotherapy is recommended for medically operable patients with nonmetastatic, locally advanced rectal cancer (LARC)...
June 27, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28800641/high-rbm3-expression-is-associated-with-an-improved-survival-and-oxaliplatin-response-in-patients-with-metastatic-colorectal-cancer
#15
Christina Siesing, Halfdan Sorbye, Anca Dragomir, Per Pfeiffer, Camilla Qvortrup, Fredrik Pontén, Karin Jirström, Bengt Glimelius, Jakob Eberhard
BACKGROUND: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. METHODS: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients...
2017: PloS One
https://www.readbyqxmd.com/read/28800321/the-impact-of-chemotherapy-associated-hemoglobin-on-prognosis-of-colorectal-cancer-patients-receiving-adjuvant-chemotherapy
#16
Yi-Sheng Wei, Ya-Guang Zhou, Guo-Ying Wang, Zhi-Hua Liang, Min-Rui Luo, Tian-Ai Yang, Jun Huang
BACKGROUND AND OBJECTIVE: The association of chemotherapy-associated hemoglobin and survival of colorectal cancer (CRC) receiving adjuvant chemotherapy is uncertain. We sought to explore the prognostic value of chemotherapy-associated hemoglobin in CRC receiving adjuvant chemotherapy and the best cut point affecting prognosis. METHODS: Three hundred and twenty stage II and III CRC patients receiving adjuvant FOLFOX chemotherapy from March 2003 to March 2012 were enrolled...
August 1, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28797089/therapeutic-response-assessment-using-3d-ultrasound-for-hepatic-metastasis-from-colorectal-cancer-application-of-a-personalized-3d-printed-tumor-model-using-ct-images
#17
Ye Ra Choi, Jung Hoon Kim, Sang Joon Park, Bo Yun Hur, Joon Koo Han
BACKGROUND & AIMS: To evaluate accuracy and reliability of three-dimensional ultrasound (3D US) for response evaluation of hepatic metastasis from colorectal cancer (CRC) using a personalized 3D-printed tumor model. METHODS: Twenty patients with liver metastasis from CRC who underwent baseline and after chemotherapy CT, were retrospectively included. Personalized 3D-printed tumor models using CT were fabricated. Two radiologists measured volume of each 3D printing model using 3D US...
2017: PloS One
https://www.readbyqxmd.com/read/28796930/recurrence-associated-gene-signature-optimizes-recurrence-free-survival-prediction-of-colorectal-cancer
#18
Xianglong Tian, Xiaoqiang Zhu, Tingting Yan, Chenyang Yu, Chaoqin Shen, Ye Hu, Jie Hong, Haoyan Chen, Jing-Yuan Fang
High throughput gene expression profiling has showed great promise in providing insight into molecular mechanisms. Metastasis-related mRNAs may potentially enrich genes with the ability to predict cancer recurrence,therefore we attempted to build a recurrence-associated gene signature to improve prognostic prediction of colorectal cancer (CRC). We identified 2848 differentially expressed mRNAs by analyzing CRC tissues with or without metastasis. For the selection of prognostic genes, a LASSO Cox regression model was employed...
August 10, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28795308/the-mean-corpuscular-volume-as-a-prognostic-factor-for-colorectal-cancer
#19
Hidemasa Nagai, Norihiro Yuasa, Eiji Takeuchi, Hideo Miyake, Yuichiro Yoshioka, Kanji Miyata
PURPOSE: The aim of the present study was to identify the factors investigated during routine blood examinations which can predict the disease outcome independent of the tumor stage. METHODS: Data from 1174 patients with stage I, II, and III CRC who underwent R0 resection were included. We investigated the correlations between the preoperative routine blood examination data, and clinicopathological factors, and disease-free survival (DFS) using univariate and multivariate analyses...
August 9, 2017: Surgery Today
https://www.readbyqxmd.com/read/28794643/preoperative-lymphocyte-to-monocyte-ratio-represents-a-superior-predictor-compared-with-neutrophil-to-lymphocyte-and-platelet-to-lymphocyte-ratios-for-colorectal-liver-only-metastases-survival
#20
Jianhong Peng, Hui Li, Qingjian Ou, Junzhong Lin, Xiaojun Wu, Zhenhai Lu, Yunfei Yuan, Desen Wan, Yujing Fang, Zhizhong Pan
Systemic inflammation was recognized as an essential factor contributing to the development of malignancies. This study aimed to investigate the prognostic value of pre-operative lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in patients with colorectal liver-only metastases (CLOM) undergoing hepatectomy. We retrospectively enrolled 150 consecutive patients with CLOM between 2000 and 2012. The optimal cutoff values of continuous LMR, NLR, and PLR were determined using the receiver operating characteristic curve analysis...
2017: OncoTargets and Therapy
keyword
keyword
40932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"